Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study

The approved dose of bosutinib in chronic phase CML is 400 mg QD in first-line and 500 mg QD in later-line treatment. However, given that gastrointestinal (GI) toxicity typically occurs early after treatment initiation, physicians often tend to start therapy with lower doses although this has never...

Descripción completa

Detalles Bibliográficos
Autores principales: Isfort, Susanne, Manz, Kirsi, Teichmann, Lino L., Crysandt, Martina, Burchert, Andreas, Hochhaus, Andreas, Saussele, Susanne, Kiani, Alexander, Göthert, Joachim R., Illmer, Thomas, Schafhausen, Philippe, Al-Ali, Haifa Kathrin, Stegelmann, Frank, Hänel, Mathias, Pfeiffer, Tim, Giagounidis, Aristoteles, Franke, Georg-Nikolaus, Koschmieder, Steffen, Fabarius, Alice, Ernst, Thomas, Warnken-Uhlich, Mareille, Wolber, Uta, Kohn, Denise, Pfirrmann, Markus, Wolf, Dominik, Brümmendorf, Tim H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492675/
https://www.ncbi.nlm.nih.gov/pubmed/37592092
http://dx.doi.org/10.1007/s00277-023-05394-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492675/
https://www.ncbi.nlm.nih.gov/pubmed/37592092
http://dx.doi.org/10.1007/s00277-023-05394-0

Ejemplares similares